Period	EPS Est.	Range	Growth	#
Current Q	$-0.08 ▲ +68.0%	$-0.08 — $-0.08		1
Next Q	$-0.19	$-0.19 — $-0.19		1
Current FY	$-0.51 ▲ +29.2%	$-0.51 — $-0.51	-113% YoY	1
Next FY	$-0.52 ▲ +32.5%	$-0.52 — $-0.52	-2% YoY	1

Latest Reports

BULLISH 6-K 8/10

Adagene presented new clinical data at AACR 2026 showing strong efficacy for muzastotug in triple combination therapies:

Apr 17, 2026

BEARISH 6-K 7/10

Adagene Inc. has entered into an underwriting agreement to raise approximately $70.0 million through the public offering

Apr 2, 2026

NEUTRAL Press 5/10

Adagene priced a public offering of 18.7M ADSs at $3.75 per share, raising approximately $70.0 million in gross proceeds

Apr 2, 2026

Top Institutional Holders

Fund	Value	Move
MORGAN STANLEY	$143.0K	—

1 institutional holders with $143.0K total value (75,645 shares) as of 2025-Q4. Top holders: MORGAN.

Top Institutional Holders — 2025-Q4

#	Fund	Shares	Value	% of Tracked	Last Move
1	MORGAN STANLEY	75,645	$143.0K	100.0%	—

Recent Position Changes

Fund	Action	Prev Shares	Curr Shares	Change %	Value	Quarter
FMR LLC	EXIT	379,159	0	-100.0%	$0.00	2025-Q3
FMR LLC	TRIM	1,181,635	379,159	-67.9%	$750.7K	2025-Q2

∅

No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.

4 SEC filing reports analyzed. Sentiment: 2 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 6.8/10.

BULLISH 6-K 8/10

Adagene presented new clinical data at AACR 2026 showing strong efficacy for muzastotug in triple co

Apr 17, 2026

BEARISH 6-K 7/10

Adagene Inc. has entered into an underwriting agreement to raise approximately $70.0 million through

Apr 2, 2026

NEUTRAL 424B5 5/10

Adagene Inc. is conducting a preliminary prospectus supplement for a public offering of American Dep

Apr 2, 2026

BULLISH 20-F, 6-K 7/10

Adagene's 20-F filing, combined with recent 6-Ks, confirms strong clinical progress for its lead can

Apr 1, 2026

NEUTRAL 5/10

Adagene priced a public offering of 18.7M ADSs at $3.75 per share, raising approximately $70.0 milli

Apr 2, 2026

BULLISH 7/10

Adagene announced a clinical collaboration with Incyte to evaluate its masked anti-CTLA-4 therapy mu

Apr 2, 2026

BULLISH 8/10

Adagene announced updated Phase 1b/2 data for muzastotug in advanced MSS CRC, showing a 31% confirme

Apr 2, 2026

NEUTRAL 5/10

Adagene Inc. announced that its lead candidate, muzastotug (ADG126), will be featured in two poster

Mar 17, 2026

Current analyst consensus: Strong Buy (83% buy). Based on 12 analysts: 4 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$9.40 mean target +176.5% upside Strong Buy (3.00)

$7.00 Low $14.00 High

Metric	Value
Current Price	$3.40
Target Low	$7.00
Target Mean	$9.40
Target Median	$8.00
Target High	$14.00
# Analysts	5
Recommendation	Strong Buy (3.00)

Earnings Estimates & Revisions

Period	EPS Avg	EPS Low	EPS High	EPS Growth	30d Rev.	Up/Down	Rev. Avg	Rev. Growth	Analysts
Current Q 2026-03-31	$-0.08	$-0.08	$-0.08	—	+68.0%	—	$0.0B	—	1
Next Q 2026-06-30	$-0.19	$-0.19	$-0.19	—	—	—	$0.0B	0.0%	1
Current FY 2026-12-31	$-0.51	$-0.51	$-0.51	-112.5%	+29.2%	1↑ 0↓	$0.0B	-100.0%	1
Next FY 2027-12-31	$-0.52	$-0.52	$-0.52	-2.0%	+32.5%	1↑ 0↓	$0.0B	0.0%	1

Current Quarter EPS Revision History

Timepoint	EPS Estimate	Change
Current	$-0.080
7d ago	$0.000	-0.080
30d ago	$-0.250	+0.170
60d ago	$-0.250	+0.170
90d ago	$-0.250	+0.170

1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.

Individual Analyst Actions

Date	Analyst Firm	Action	Previous Rating	New Rating
Apr 6, 2026	Guggenheim	MAINTAIN	Buy	Buy

Monthly Consensus History

Period	Strong Buy	Buy	Hold	Buy %
Jun 1, 2026	4	6	2	83%
May 1, 2026	4	7	2	85%
Apr 1, 2026	4	7	2	85%
Mar 1, 2026	4	7	2	85%
Feb 1, 2026	4	7	3	79%
Jan 1, 2026	4	7	3	79%

Strong BuyBuyHoldSellStrong Sell

∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 12, 2026

other

Adagene to Participate in Two Upcoming Investor Conferences

SAN DIEGO and SUZHOU, China, May 12, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company tran

Apr 17, 2026

other

Adagene Presents Two Posters at AACR 2026 with New Data Highlighting Muzastotug’s Potential as a Backbone Combination Therapy for Multiple Tumor Types

Triple combination of muzastotug + atezolizumab + bevacizumab resulted in much higher overall response rates (ORR) compared to t

Apr 2, 2026

activist

Adagene Announces Pricing of US$70.0 Million Public Offering of ADSs

SAN DIEGO and SUZHOU, China, April 02, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene” or the “Company”) (Nasdaq: ADAG), a compa

Apr 2, 2026

fda

Adagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte’s TGFßR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)

Phase 1 study of INCA33890 and muzastotug expected to begin in 2026 in 3L MSS CRC patients with and without liver metas

Apr 2, 2026

fda

Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Late-line Patients with Microsatellite Stable Colorectal Cancer Demonstrate Improved Durability of Response

Dose-Dependent Efficacy Results: As of the latest data cut, muzastotug achieved a 31% (8/26)

Apr 1, 2026

earnings

Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update

In 2025, muzastotug showed 29% confirmed overall response rate (ORR) among 21 patients with MSS CRC in the 20 mg/kg dos

Mar 23, 2026

earnings_calendar

ADAG Q4 2025 Earnings After Market Close — 2026-03-23

Mar 17, 2026

fda

Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA

SAN DIEGO and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company